AKERO THERAPEUTICS INC's ticker is AKRO and the CUSIP is 00973Y108. A total of 99 filers reported holding AKERO THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2022 | $4,000 | -87.5% | 398 | -82.2% | 0.00% | -100.0% |
| Q1 2022 | $32,000 | +113.3% | 2,242 | +244.9% | 0.00% | – |
| Q3 2021 | $15,000 | -77.9% | 650 | -76.1% | 0.00% | -100.0% |
| Q2 2021 | $68,000 | +750.0% | 2,723 | +951.4% | 0.00% | – |
| Q1 2021 | $8,000 | -46.7% | 259 | -56.5% | 0.00% | -100.0% |
| Q4 2020 | $15,000 | -11.8% | 595 | +5.1% | 0.00% | -50.0% |
| Q3 2020 | $17,000 | +88.9% | 566 | +55.5% | 0.00% | +100.0% |
| Q2 2020 | $9,000 | +800.0% | 364 | +1113.3% | 0.00% | – |
| Q1 2020 | $1,000 | -85.7% | 30 | -91.0% | 0.00% | -100.0% |
| Q4 2019 | $7,000 | -90.9% | 332 | -91.7% | 0.00% | -90.5% |
| Q2 2019 | $77,000 | – | 4,008 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ATP Life Science Ventures, L.P. | 5,830,203 | $179,512,000 | 24.20% |
| venBio Partners LLC | 2,444,311 | $75,260,000 | 11.44% |
| Versant Venture Management, LLC | 777,727 | $23,946,000 | 4.38% |
| Redmile Group, LLC | 2,336,357 | $71,936,000 | 1.32% |
| Vivo Capital, LLC | 571,833 | $17,607,000 | 1.02% |
| Cormorant Asset Management, LP | 859,550 | $26,466,000 | 1.02% |
| Boxer Capital, LLC | 831,495 | $25,602,000 | 0.88% |
| Integral Health Asset Management, LLC | 85,000 | $2,617,000 | 0.80% |
| EAM Global Investors LLC | 49,718 | $1,531,000 | 0.56% |
| Crawford Lake Capital Management, LLC | 43,826 | $1,349,000 | 0.56% |